Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Silicon Laboratories Q3 2026 Results: Turns Profitable, Net Income $8.85M

Silicon Laboratories reported a return to profitability in the third quarter of 2026 with net income of $8.9 million, compared to a net loss of $9.9 million in the prior year period. However, for the nine months ended October 3, 2026, the company remains in a net loss position of $17.6 million as revenues grew to $692.6 million from $576.6 million year-over-year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue250.9206.0
Gross profit152.6119.0
Profit before tax10.9-9.5
Net income8.9-9.9
EPS (diluted, $ a share)$0.26$-0.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+21.8%
Gross margin60.8%
Operating margin3.2%
Source

10-Q filed with the SEC, NASDAQ: SLAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Silicon Laboratories Inc.: key numbers

Share price
$221.65Close, Nov 16
Market cap
$7.4B
Shares outstanding
33.38MLatest SEC cover page
Sector
Manufacturing
Industry
Semiconductors & Related DevicesSIC 3674

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Silicon Laboratories Inc.

All →
4:08 PM ET 8-K
Financial Results

Silicon Laboratories Financial Results

Silicon Laboratories reported Q3 2026 revenue of $251 million, a 22% year-over-year increase driven by record medical revenue and broad-based growth in Industrial & Commercial and Home & Life segments. GAAP diluted EPS improved to $0.26 from a loss in the prior year, while non-GAAP EPS rose 228% to $1.05. The company suspended forward-looking guidance due to its pending acquisition by Texas Instruments.

Term
Q3 2026

“We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued. Earnings significantly outpaced revenue growth, a result of strong operational execution by the team. Looking ahead, our current backlog and design-win ramps position us for continued revenue growth and meaningful earnings expansion.”

Matt Johnson, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.